From Cure Today:
We are entering the “Golden Age” of kidney cancer care, says James Hsieh, M.D., Ph.D., medical oncologist, Memorial Sloan Kettering Cancer Center. “I see a future where we can take a look at a patient’s cancer genomics, figure out what kind of treatment they will benefit from as a frontline, and then we can use a very good combination like VEGF treatment plus PD-1/PD-L1, and I think we should be able to achieve very durable remission for 30 percent or more of kidney cancer patients,” he said.
Read the full article.
